$OCUL
OCULAR THERAPEUTIX, INC

2023 Q2 Form 10-Q Financial Statement

#000155837023008510 Filed on May 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $15.19M $13.37M
YoY Change 23.81% 1.42%
Cost Of Revenue $1.304M $1.214M
YoY Change 12.9% -6.62%
Gross Profit $13.88M $12.16M
YoY Change 24.94% 2.3%
Gross Profit Margin 91.41% 90.92%
Selling, General & Admin $19.36M $19.96M
YoY Change 7.98% 20.11%
% of Gross Profit 139.45% 164.16%
Research & Development $15.09M $14.75M
YoY Change 15.22% 12.57%
% of Gross Profit 108.73% 121.27%
Depreciation & Amortization $652.0K $483.0K
YoY Change 18.12% -13.29%
% of Gross Profit 4.7% 3.97%
Operating Expenses $34.45M $34.71M
YoY Change 11.04% 16.79%
Operating Profit -$20.57M -$22.55M
YoY Change 3.28% 26.45%
Interest Expense -$112.0K $1.768M
YoY Change -106.6% 5.05%
% of Operating Profit
Other Income/Expense, Net $0.00 -$7.769M
YoY Change -100.0% -246.83%
Pretax Income -$20.68M -$30.32M
YoY Change 10.21% 141.73%
Income Tax
% Of Pretax Income
Net Earnings -$20.68M -$30.32M
YoY Change 10.21% 141.73%
Net Earnings / Revenue -136.19% -226.69%
Basic Earnings Per Share -$0.26 -$0.39
Diluted Earnings Per Share -$0.27 -$0.39
COMMON SHARES
Basic Shares Outstanding 77.52M 77.51M
Diluted Shares Outstanding 78.05M 77.39M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $66.61M $79.03M
YoY Change -50.49% -45.66%
Cash & Equivalents $66.61M $79.03M
Short-Term Investments
Other Short-Term Assets $4.593M $4.746M
YoY Change 20.84% 1.63%
Inventory $2.204M $2.266M
Prepaid Expenses
Receivables $27.31M $21.12M
Other Receivables $0.00 $0.00
Total Short-Term Assets $100.7M $107.2M
YoY Change -37.18% -38.64%
LONG-TERM ASSETS
Property, Plant & Equipment $20.08M $12.02M
YoY Change 200.63% 81.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.764M $1.764M
YoY Change 0.0% 0.0%
Total Long-Term Assets $21.85M $21.41M
YoY Change 71.35% 65.08%
TOTAL ASSETS
Total Short-Term Assets $100.7M $107.2M
Total Long-Term Assets $21.85M $21.41M
Total Assets $122.6M $128.6M
YoY Change -29.19% -31.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.572M $5.441M
YoY Change -3.54% 59.09%
Accrued Expenses $26.31M $21.99M
YoY Change 35.28% 24.71%
Deferred Revenue $391.0K $463.0K
YoY Change -67.12% -61.67%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $2.083M
YoY Change
Total Short-Term Liabilities $32.36M $29.72M
YoY Change 23.91% 24.02%
LONG-TERM LIABILITIES
Long-Term Debt $53.28M $54.68M
YoY Change 1.12% 5.03%
Other Long-Term Liabilities $33.83M $100.0K
YoY Change 18.87% -99.69%
Total Long-Term Liabilities $87.11M $100.0K
YoY Change 7.34% -99.88%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.36M $29.72M
Total Long-Term Liabilities $87.11M $100.0K
Total Liabilities $119.5M $118.9M
YoY Change 11.38% 10.23%
SHAREHOLDERS EQUITY
Retained Earnings -$667.8M -$647.2M
YoY Change 15.72% 15.91%
Common Stock $670.9M $656.9M
YoY Change 4.36% 2.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.087M $9.711M
YoY Change
Total Liabilities & Shareholders Equity $122.6M $128.6M
YoY Change -29.19% -31.47%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$20.68M -$30.32M
YoY Change 10.21% 141.73%
Depreciation, Depletion And Amortization $652.0K $483.0K
YoY Change 18.12% -13.29%
Cash From Operating Activities -$20.08M -$19.97M
YoY Change 84.58% 7.38%
INVESTING ACTIVITIES
Capital Expenditures $1.990M $3.379M
YoY Change -502.02% 1124.28%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.990M -$3.379M
YoY Change 302.02% 1124.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.645M 78.00K
YoY Change 1856.39% -39.53%
NET CHANGE
Cash From Operating Activities -20.08M -19.97M
Cash From Investing Activities -1.990M -3.379M
Cash From Financing Activities 9.645M 78.00K
Net Change In Cash -12.42M -23.27M
YoY Change 14.18% 24.15%
FREE CASH FLOW
Cash From Operating Activities -$20.08M -$19.97M
Capital Expenditures $1.990M $3.379M
Free Cash Flow -$22.07M -$23.35M
YoY Change 112.55% 23.71%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
12914000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2072000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
718000
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2022Q1 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77516638
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77201819
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001393434
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-36554
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Ocular Therapeutix, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-5560161
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
24 Crosby Drive
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Bedford
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01730
CY2023Q1 dei City Area Code
CityAreaCode
781
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
357-4000
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2023Q1 dei Trading Symbol
TradingSymbol
OCUL
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
77524666
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79026000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
102300000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
21124000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
21325000
CY2023Q1 us-gaap Inventory Net
InventoryNet
2266000
CY2022Q4 us-gaap Inventory Net
InventoryNet
1974000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4746000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4028000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
107162000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
129627000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12022000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9856000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7625000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8042000
CY2023Q1 us-gaap Assets
Assets
128573000
CY2022Q4 us-gaap Assets
Assets
149289000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5441000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5123000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21993000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24097000
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
463000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
576000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1818000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1599000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
29715000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
31395000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8114000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8678000
CY2023Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
12914000
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
6351000
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
13340000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
13387000
CY2023Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
25321000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
25257000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
100000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
93000
CY2023Q1 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
29358000
CY2022Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
28749000
CY2023Q1 us-gaap Liabilities
Liabilities
118862000
CY2022Q4 us-gaap Liabilities
Liabilities
113910000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77516638
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77201819
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
8000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
656863000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
652213000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-647160000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-616842000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
9711000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
35379000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
128573000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
149289000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13374000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13187000
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1214000
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1300000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14747000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13100000
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10835000
CY2022Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9063000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9127000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7557000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
35923000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
31020000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-22549000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-17833000
CY2023Q1 us-gaap Investment Income Net
InvestmentIncomeNet
563000
CY2022Q1 us-gaap Investment Income Net
InvestmentIncomeNet
18000
CY2023Q1 us-gaap Interest Expense
InterestExpense
1768000
CY2022Q1 us-gaap Interest Expense
InterestExpense
1683000
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-6563000
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
6958000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7769000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5291000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-30318000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-12542000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77386287
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76745663
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77386287
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82514895
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-30318000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-12542000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4572000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4209000
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1228000
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1186000
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-6563000
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
6958000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
483000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
557000
CY2023Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
1000
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-201000
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24024233
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-81000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
292000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
108000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1025000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1113000
CY2023Q1 ocul Increase Decrease In Operating Lease Asset And Liability
IncreaseDecreaseInOperatingLeaseAssetAndLiability
72000
CY2022Q1 ocul Increase Decrease In Operating Lease Asset And Liability
IncreaseDecreaseInOperatingLeaseAssetAndLiability
-105000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2628000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3048000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-160000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1311000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19973000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18600000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3379000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
276000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3379000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-276000
CY2023Q1 ocul Proceeds From Issuance Of Protective Advance
ProceedsFromIssuanceOfProtectiveAdvance
2000000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
78000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
129000
CY2023Q1 ocul Repayment Of Protective Advance
RepaymentOfProtectiveAdvance
2000000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
78000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
129000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-23274000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18747000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104064000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
165928000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80790000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
147181000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
701000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
495000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
646000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
123000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
35379000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
78000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4572000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-30318000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
9711000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
87999000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
129000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4209000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-12542000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
79795000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-647160000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79026000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14544284
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
13963000
CY2023Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
160000
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
13803000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79026000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
145417000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80790000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
147181000
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
228000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
309000
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
773000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
899000
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1265000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
766000
CY2023Q1 us-gaap Inventory Net
InventoryNet
2266000
CY2022Q4 us-gaap Inventory Net
InventoryNet
1974000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4527000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7509000
CY2023Q1 ocul Accrued Rebates And Programs Current
AccruedRebatesAndProgramsCurrent
3914000
CY2022Q4 ocul Accrued Rebates And Programs Current
AccruedRebatesAndProgramsCurrent
3560000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1035000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1228000
CY2023Q1 ocul Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1947000
CY2022Q4 ocul Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1816000
CY2023Q1 ocul Debt Instrument Accrued Interest
DebtInstrumentAccruedInterest
9191000
CY2022Q4 ocul Debt Instrument Accrued Interest
DebtInstrumentAccruedInterest
8756000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1379000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1228000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21993000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24097000
CY2023Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-6563000
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
6351000
CY2023Q1 ocul Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsForfeituresAndExpirationsInPeriod
131347
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4572000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4209000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
26118000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M29D
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-30318000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-12542000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77386287
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76745663
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12542000
CY2022Q1 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
1123000
CY2022Q1 us-gaap Dilutive Securities
DilutiveSecurities
-6958000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-18377000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76745663
CY2022Q1 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
5769232
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82514895
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22

Files In Submission

Name View Source Status
ocul-20230331_pre.xml Edgar Link unprocessable
ocul-20230331_cal.xml Edgar Link unprocessable
0001558370-23-008510-index-headers.html Edgar Link pending
0001558370-23-008510-index.html Edgar Link pending
0001558370-23-008510.txt Edgar Link pending
0001558370-23-008510-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ocul-20230331.xsd Edgar Link pending
ocul-20230331x10q.htm Edgar Link pending
ocul-20230331xex10d1.htm Edgar Link pending
ocul-20230331xex31d1.htm Edgar Link pending
ocul-20230331xex31d2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ocul-20230331x10q_htm.xml Edgar Link completed
ocul-20230331xex32d1.htm Edgar Link pending
ocul-20230331xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
ocul-20230331_def.xml Edgar Link unprocessable
ocul-20230331_lab.xml Edgar Link unprocessable
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending